Editas Medicine, Inc. (EDIT) SEC Filings & Earnings Calls

Clinical trial risk: early-stage trial may fail to show safety or efficacy

“Phase 1/2 trial is first-in-human; initial safety data expected Q1 2027; topline data later in 2027.”

Clinical failure risk

“All of our ongoing research programs are still in the preclinical or research stage of development and the risk of failure of all of our research programs is high.” · word for word

Funding dependency

“We will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.” · word for word

No product revenue

“We have not generated any revenue from product sales, and we do not expect to generate any revenue from product sales for the foreseeable future.” · word for word

Clinical trial risk; no approved products yet

“EDIT-401 still in preclinical stage; Phase 1/2 trial not yet initiated”

Dilution risk from large equity offering; warrants could further dilute if exercised.

“55,555,556 shares offered at $2.25; warrants for additional 55,555,556 shares at $3.50.”

Cash burn risk remains high; pre-revenue biotech with no approved products.

“Pre-revenue company; proceeds extend runway but no revenue visibility.”

Preclinical data may not translate to human efficacy; clinical trial risks remain high.

“Results of preclinical studies may not be predictive of the results of clinical trials.”

Regulatory approval risk for CTN and IND; potential delays.

“These clinical trial plans are subject to further discussion and alignment with regulatory authorities.” · word for word

No material risk; suspension is procedural after larger offering.

“Sales agreement remains in full force and effect; suspension is temporary.” · word for word

Preclinical data, not yet in human trials; risk of failure in later stages.

“Data from non-human primates; IND submission expected H2 2026.”

Patent dispute with Broad Institute poses risk to CRISPR/Cas9 licensing; CVC may appeal, creating uncertainty.

“PTAB reaffirmed Broad Institute patent win; CVC retains right to appeal”

Cash runway only into Q3 2027; will likely need to raise additional capital before reaching profitability.

“Existing cash will fund operations into Q3 2027”

Patent interference risk

“If we or our licensors are unsuccessful in any patent related disputes, including interference proceedings, patent oppositions, re-examinations, or other priority, inventorship, or validity disputes to which we or they are subject (including any of the proceedings discussed above), we may lose valuable intellectual property rights.” · word for word

Funding risk

“If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce, or terminate our product development or future commercialization efforts.” · word for word

Low say-on-pay support

“Approximately 61% of the votes cast on this proposal approved of the compensation paid to the named executive officers” · word for word

Preclinical stage risk

“we accelerated our strategy to become a leader in in vivo gene editing by transitioning to a fully in vivo focused preclinical company” · word for word

Auditor change may signal increased scrutiny or internal control review, though no disagreements reported.

“No disagreements or reportable events; change appears routine after competitive review.”

CVC retains right to appeal, creating ongoing legal uncertainty.

“CVC retains the right to appeal the decision to the CAFC.” · word for word

Program discontinuation risk

“In December 2024, our board of directors approved the discontinuation of the clinical development of our ex vivo reni-cel program.” · word for word

Dependence on collaborations for revenue

“For the foreseeable future we expect substantially all of our revenue will be generated from the Vertex License Agreement, our collaboration with BMS, and any other collaborations or license agreements we may enter into.” · word for word

Cash runway limited

“We expect that our existing cash and cash equivalents on December 31, 2025 will enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2027.” · word for word

Pre-revenue gene editing company with significant cash burn; reliance on pipeline success and partnership revenue.

“Net loss $160.1M in FY2025; cash burn rate; no approved products.”

Clinical development risk for EDIT-401; IND/CTA submission and human proof-of-concept data not yet achieved.

“Company on track to submit IND/CTA by mid-2026 and achieve initial human proof-of-concept data by year-end 2026.” · word for word

Dependence on ATM facility for cash runway extension; potential dilution.

“Extended cash runway into Q3 2027 with proceeds from sales of common stock under ATM facility.”

Cash runway risk

“We will need to obtain substantial additional funding in connection with our continuing operations.” · word for word

Clinical failure risk

“All of our ongoing research programs are still in the preclinical or research stage of development and the risk of failure of all of our research programs is high.” · word for word

Dilution risk

“To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders' ownership interests will be diluted.” · word for word